title: Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.
abstract: OBJECTIVE
  To explore the potential of dexrazoxane to suppress subclinical cardiotoxicity in MS patients receiving mitoxantrone.
  
  
  METHODS
  An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48 mg/m(2) cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography.
  
  
  RESULTS
  No patient experienced symptoms of heart failure. Patients receiving dexrazoxane, which is cardioprotective for anthracyclines, exhibited a significantly lesser decline in left ventricular ejection fraction (mean change, -3.80% vs -8.55%, p < 0.001).
  
  
  CONCLUSIONS
  These results support a cardioprotective effect of dexrazoxane in mitoxantrone treated multiple sclerosis patients.
authors.affiliation: Department of Neurology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0322, USA.
authors.forename: Evanthia
authors.initials: E
authors.lastname: Bernitsas
authors.forename: Wei
authors.initials: W
authors.lastname: Wei
authors.forename: Daniel D
authors.initials: DD
authors.lastname: Mikol
mesh_terms: D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D002317:Cardiovascular Agents / Q000378:metabolism / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use / Q000633:toxicity; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011929:Razoxane / Q000378:metabolism / Q000627:therapeutic use; D013318:Stroke Volume; D019210:Troponin I / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D002317:Cardiovascular Agents; D019210:Troponin I; D011929:Razoxane; D008942:Mitoxantrone